Is PTCT or MRNA more profitable?

PTC Therapeutics has a net margin of -22.58% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -22.58% -362.45% -6.76% Moderna -143.55% -26.64% -19.32%

Does the media favor PTCT or MRNA?

In the previous week, Moderna had 6 more articles in the media than PTC Therapeutics. MarketBeat recorded 21 mentions for Moderna and 15 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.68 beat Moderna's score of 0.55 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTCT or BNTX?

In the previous week, PTC Therapeutics had 11 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for PTC Therapeutics and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.37 beat PTC Therapeutics' score of 0.68 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or PTCT?

In the previous week, Roivant Sciences had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 16 mentions for Roivant Sciences and 15 mentions for PTC Therapeutics. Roivant Sciences' average media sentiment score of 1.12 beat PTC Therapeutics' score of 0.68 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PTCT or INSM?

PTC Therapeutics has higher revenue and earnings than Insmed. PTC Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PTC Therapeutics $1.73B 3.91 $682.64M -$2.33 N/A Insmed $606.42M 38.11 -$1.28B -$5.75 N/A

Is PTCT or INSM more profitable?

PTC Therapeutics has a net margin of -22.58% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -22.58% -362.45% -6.76% Insmed -144.44% -130.11% -51.57%

Does the media favor PTCT or INSM?

In the previous week, Insmed had 4 more articles in the media than PTC Therapeutics. MarketBeat recorded 19 mentions for Insmed and 15 mentions for PTC Therapeutics. Insmed's average media sentiment score of 0.96 beat PTC Therapeutics' score of 0.68 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VTRS or PTCT more profitable?

Viatris has a net margin of -2.04% compared to PTC Therapeutics' net margin of -22.58%. Viatris' return on equity of 19.04% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% PTC Therapeutics -22.58% -362.45% -6.76%

Does the media prefer VTRS or PTCT?

In the previous week, PTC Therapeutics had 11 more articles in the media than Viatris. MarketBeat recorded 15 mentions for PTC Therapeutics and 4 mentions for Viatris. PTC Therapeutics' average media sentiment score of 0.68 beat Viatris' score of 0.54 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PTC Therapeutics (PTCT) Competitors

$81.57 0.00 (0.00%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$81.57 0.00 (0.00%)

As of 06/30/2026 04:59 PM Eastern

Compare

PTCT vs. MRNA, BNTX, ROIV, INSM, and VTRS

Should you buy PTC Therapeutics stock or one of its competitors? MarketBeat compares PTC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PTC Therapeutics include Moderna (MRNA), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does PTC Therapeutics compare to Moderna?

PTC Therapeutics (NASDAQ:PTCT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

PTC Therapeutics has higher earnings, but lower revenue than Moderna. PTC Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.91	$682.64M	-$2.33	N/A
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A

In the previous week, Moderna had 6 more articles in the media than PTC Therapeutics. MarketBeat recorded 21 mentions for Moderna and 15 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.68 beat Moderna's score of 0.55 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics currently has a consensus price target of $91.36, indicating a potential upside of 12.00%. Moderna has a consensus price target of $37.13, indicating a potential downside of 46.98%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe PTC Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

PTC Therapeutics has a net margin of -22.58% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Moderna	-143.55%	-26.64%	-19.32%

75.3% of Moderna shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PTC Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Summary

PTC Therapeutics beats Moderna on 9 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to BioNTech?

PTC Therapeutics (NASDAQ:PTCT) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, PTC Therapeutics had 11 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for PTC Therapeutics and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.37 beat PTC Therapeutics' score of 0.68 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics currently has a consensus target price of $91.36, suggesting a potential upside of 12.00%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 39.24%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

PTC Therapeutics has higher earnings, but lower revenue than BioNTech. PTC Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.91	$682.64M	-$2.33	N/A
BioNTech	$3.25B	7.25	-$1.29B	-$5.88	N/A

PTC Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

15.5% of BioNTech shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

PTC Therapeutics has a net margin of -22.58% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

BioNTech beats PTC Therapeutics on 12 of the 16 factors compared between the two stocks.

How does PTC Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 5.08%. PTC Therapeutics has a consensus target price of $91.36, indicating a potential upside of 12.00%. Given PTC Therapeutics' higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71

64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PTC Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,081.71	-$299.77M	-$0.60	N/A
PTC Therapeutics	$1.73B	3.91	$682.64M	-$2.33	N/A

PTC Therapeutics has a net margin of -22.58% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

In the previous week, Roivant Sciences had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 16 mentions for Roivant Sciences and 15 mentions for PTC Therapeutics. Roivant Sciences' average media sentiment score of 1.12 beat PTC Therapeutics' score of 0.68 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does PTC Therapeutics compare to Insmed?

PTC Therapeutics (NASDAQ:PTCT) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

PTC Therapeutics currently has a consensus price target of $91.36, indicating a potential upside of 12.00%. Insmed has a consensus price target of $211.86, indicating a potential upside of 98.71%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Insmed had 4 more articles in the media than PTC Therapeutics. MarketBeat recorded 19 mentions for Insmed and 15 mentions for PTC Therapeutics. Insmed's average media sentiment score of 0.96 beat PTC Therapeutics' score of 0.68 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

PTC Therapeutics has a net margin of -22.58% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Insmed	-144.44%	-130.11%	-51.57%

PTC Therapeutics has higher revenue and earnings than Insmed. PTC Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.91	$682.64M	-$2.33	N/A
Insmed	$606.42M	38.11	-$1.28B	-$5.75	N/A

Summary

Insmed beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

How does PTC Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Viatris currently has a consensus price target of $17.50, indicating a potential upside of 10.20%. PTC Therapeutics has a consensus price target of $91.36, indicating a potential upside of 12.00%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71

Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Viatris has a net margin of -2.04% compared to PTC Therapeutics' net margin of -22.58%. Viatris' return on equity of 19.04% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

In the previous week, PTC Therapeutics had 11 more articles in the media than Viatris. MarketBeat recorded 15 mentions for PTC Therapeutics and 4 mentions for Viatris. PTC Therapeutics' average media sentiment score of 0.68 beat Viatris' score of 0.54 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.29	-$3.51B	-$0.26	N/A
PTC Therapeutics	$1.73B	3.91	$682.64M	-$2.33	N/A

Summary

PTC Therapeutics beats Viatris on 10 of the 17 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTCT vs. The Competition

Export

Metric	PTC Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.77B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-35.01	20.90	27.25	24.87
Price / Sales	3.91	341.80	540.68	102.84
Price / Cash	9.29	143.77	48.53	58.59
Price / Book	-31.86	8.75	11.01	6.54
Net Income	$682.64M	$23.81M	$3.57B	$336.70M
7 Day Performance	-3.36%	3.60%	2.31%	2.88%
1 Month Performance	10.53%	3.72%	1.39%	0.64%
1 Year Performance	67.87%	68.80%	36.71%	31.34%

PTC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTCT PTC Therapeutics	2.8693 of 5 stars	$81.57 flat	$91.36 +12.0%	+67.0%	$6.77B	$1.73B	N/A	1,410	Insider Trade
MRNA Moderna	1.1051 of 5 stars	$59.35 -7.2%	$36.60 -38.3%	+153.8%	$25.38B	$1.94B	N/A	4,700
BNTX BioNTech	4.1328 of 5 stars	$90.19 -0.8%	$129.56 +43.7%	-12.6%	$22.98B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.0251 of 5 stars	$31.25 -0.6%	$33.59 +7.5%	+214.0%	$22.61B	$8.26M	N/A	860	Positive News Insider Trade
INSM Insmed	3.7145 of 5 stars	$98.61 +2.9%	$211.86 +114.9%	+5.9%	$20.76B	$606.42M	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTCT) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Competitors

PTCT vs. MRNA, BNTX, ROIV, INSM, and VTRS

How does PTC Therapeutics compare to Moderna?

Summary

How does PTC Therapeutics compare to BioNTech?

Summary

How does PTC Therapeutics compare to Roivant Sciences?

Summary

How does PTC Therapeutics compare to Insmed?

Summary

How does PTC Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Competitors

PTCT vs. MRNA, BNTX, ROIV, INSM, and VTRS

How does PTC Therapeutics compare to Moderna?

Which has higher valuation and earnings, PTCT or MRNA?

Does the media favor PTCT or MRNA?

Do analysts rate PTCT or MRNA?

Is PTCT or MRNA more profitable?

Do institutionals & insiders believe in PTCT or MRNA?

Which has more volatility and risk, PTCT or MRNA?

Summary

How does PTC Therapeutics compare to BioNTech?

Does the media favor PTCT or BNTX?

Do analysts prefer PTCT or BNTX?

Which has higher earnings and valuation, PTCT or BNTX?

Which has more risk and volatility, PTCT or BNTX?

Do institutionals and insiders believe in PTCT or BNTX?

Is PTCT or BNTX more profitable?

Summary

How does PTC Therapeutics compare to Roivant Sciences?

Which has more risk and volatility, ROIV or PTCT?

Do analysts rate ROIV or PTCT?

Do institutionals & insiders have more ownership in ROIV or PTCT?

Which has preferable valuation and earnings, ROIV or PTCT?

Is ROIV or PTCT more profitable?

Does the media prefer ROIV or PTCT?

Summary

How does PTC Therapeutics compare to Insmed?

Do analysts recommend PTCT or INSM?

Does the media favor PTCT or INSM?

Which has more risk & volatility, PTCT or INSM?

Is PTCT or INSM more profitable?

Which has higher valuation and earnings, PTCT or INSM?

Summary

How does PTC Therapeutics compare to Viatris?

Do analysts recommend VTRS or PTCT?

Which has more risk & volatility, VTRS or PTCT?

Do insiders and institutionals believe in VTRS or PTCT?

Is VTRS or PTCT more profitable?

Does the media prefer VTRS or PTCT?

Which has higher valuation and earnings, VTRS or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools